Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02312544 · ClinicalTrials.gov registry record · Phase 2
Phase 2b Study Evaluating Safety and Efficacy of OTX-TP Compared to Timolol Drops in the Treatment of Subjects With Open Angle Glaucoma or Ocular Hypertension
A Phase 2 study, sponsored by Ocular Therapeutix.
- Completed
- Registry status
- Phase 2
- Development phase
- 72
- Enrollment target
NCT02312544 is a Phase 2 study that has completed, run by Ocular Therapeutix. The registered enrollment target is 72 participants.
The verdict
NCT02312544, a Phase 2 study, has completed, sponsored by Ocular Therapeutix.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 72 participants
- Enrollment target
Study Summary
To evaluate the safety and IOP lowering efficacy of OTX-TP, a sustained release travoprost drug product, placed in the canaliculus of the eyelid compared to Timolol Maleate Ophthalmic Solution, 0.5% in the treatment of subjects with open angle glaucoma or ocular hypertension. The study is designed to assess clinically meaningful response to treatment and is not powered to measure any efficacy endpoints with statistical significance.
Interventions
- DRUG Timolol
- DRUG OTX-TP
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 72 participants |
| Start Date | 2014-11 |
| Est. Completion | 2015-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02312544
The ClinicalTrials.gov registry entry for NCT02312544 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 72 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Ocular Therapeutix, which has 20 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Timolol is the first listed.
NCT02312544 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02312544 about?
NCT02312544 is a clinical study titled "Phase 2b Study Evaluating Safety and Efficacy of OTX-TP Compared to Timolol Drops in the Treatment of Subjects With Open Angle Glaucoma or Ocular Hypertension". To evaluate the safety and IOP lowering efficacy of OTX-TP, a sustained release travoprost drug product, placed in the canaliculus of the eyelid compared to Timolol Maleate Ophthalmic Solution, 0.5% in the treatment of subjects with open angle glaucoma or ocular hypertension. The study is designed t...
What is the current status of trial NCT02312544?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 72 participants. The study started on 2014-11. Estimated completion is 2015-12.
What interventions are being tested in trial NCT02312544?
The interventions under investigation include: Timolol (DRUG), OTX-TP (DRUG).
Who is sponsoring clinical trial NCT02312544?
This trial is sponsored by Ocular Therapeutix, which has 20 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.